Wed Sep 25 08:18:48 UTC 2024: ## vTv Therapeutics Stock Dips Below Key Moving Average
**New York, NY (September 25, 2024)** – Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) closed below their 50-day moving average on Tuesday, signaling potential weakness in the stock. The stock traded as low as $13.21, falling below the 50-day moving average of $16.01. Volume for the day was 6,966 shares.
vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for metabolic and inflammatory diseases. Their lead drug candidate, cadisegliatin (TTP399), is in Phase III clinical trials for treating type 1 and type 2 diabetes. The company also has other promising drug candidates in development.
Despite this recent dip, vTv Therapeutics has a market cap of $39.76 million, a PE ratio of -1.49, and a beta of 0.65. The company’s last quarterly earnings report, released on August 8th, showed a loss of $0.81 per share.
Investors are watching closely to see if vTv Therapeutics can rebound from this recent decline. The company’s future success will likely hinge on the results of their ongoing clinical trials and the overall performance of the biotechnology sector.
First Piper 